High-throughput screening-driven lead discovery: Meeting the challenges of finding new therapeutics

Research output: Contribution to journalArticle

51 Citations (Scopus)

Abstract

The pharmaceutical industry faces a number of challenges that have cumulatively led to a decline in productivity, despite increasing levels of investment in research and development. It is in this context that some researchers and business analysts are questioning the value of the high-throughput screening (HTS) paradigm for the discovery of new therapeutics. While this criticism may be premature, significant changes are occurring in HTS-driven lead discovery to address the failure of drug candidates in the clinic. This article highlights some of these changes and their potential impact.

Original languageEnglish (US)
Pages (from-to)487-494
Number of pages8
JournalCurrent Opinion in Drug Discovery and Development
Volume8
Issue number4
StatePublished - Jul 2005

Fingerprint

Drug Industry
Research Personnel
Research
Pharmaceutical Preparations
Therapeutics
Lead

Keywords

  • ADME
  • High-throughput screening
  • Lead discovery
  • Medicinal chemistry
  • Toxicology
  • Virtual screening

ASJC Scopus subject areas

  • Molecular Medicine
  • Pharmacology
  • Drug Discovery

Cite this

@article{05cf442937a54f4baad99d18961359e5,
title = "High-throughput screening-driven lead discovery: Meeting the challenges of finding new therapeutics",
abstract = "The pharmaceutical industry faces a number of challenges that have cumulatively led to a decline in productivity, despite increasing levels of investment in research and development. It is in this context that some researchers and business analysts are questioning the value of the high-throughput screening (HTS) paradigm for the discovery of new therapeutics. While this criticism may be premature, significant changes are occurring in HTS-driven lead discovery to address the failure of drug candidates in the clinic. This article highlights some of these changes and their potential impact.",
keywords = "ADME, High-throughput screening, Lead discovery, Medicinal chemistry, Toxicology, Virtual screening",
author = "Posner, {Bruce A.}",
year = "2005",
month = "7",
language = "English (US)",
volume = "8",
pages = "487--494",
journal = "Current Opinion in Drug Discovery and Development",
issn = "1367-6733",
publisher = "Current Drugs Ltd.",
number = "4",

}

TY - JOUR

T1 - High-throughput screening-driven lead discovery

T2 - Meeting the challenges of finding new therapeutics

AU - Posner, Bruce A.

PY - 2005/7

Y1 - 2005/7

N2 - The pharmaceutical industry faces a number of challenges that have cumulatively led to a decline in productivity, despite increasing levels of investment in research and development. It is in this context that some researchers and business analysts are questioning the value of the high-throughput screening (HTS) paradigm for the discovery of new therapeutics. While this criticism may be premature, significant changes are occurring in HTS-driven lead discovery to address the failure of drug candidates in the clinic. This article highlights some of these changes and their potential impact.

AB - The pharmaceutical industry faces a number of challenges that have cumulatively led to a decline in productivity, despite increasing levels of investment in research and development. It is in this context that some researchers and business analysts are questioning the value of the high-throughput screening (HTS) paradigm for the discovery of new therapeutics. While this criticism may be premature, significant changes are occurring in HTS-driven lead discovery to address the failure of drug candidates in the clinic. This article highlights some of these changes and their potential impact.

KW - ADME

KW - High-throughput screening

KW - Lead discovery

KW - Medicinal chemistry

KW - Toxicology

KW - Virtual screening

UR - http://www.scopus.com/inward/record.url?scp=21444453119&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=21444453119&partnerID=8YFLogxK

M3 - Article

C2 - 16022185

AN - SCOPUS:21444453119

VL - 8

SP - 487

EP - 494

JO - Current Opinion in Drug Discovery and Development

JF - Current Opinion in Drug Discovery and Development

SN - 1367-6733

IS - 4

ER -